Related Experiment Videos
An overview of combined heart and kidney transplantation
J A Castillo-Lugo1, K R Brinker
1Dallas Nephrology Associates, TX 75208, USA.
Insights
Combined heart-kidney transplants (HNTx) show promising reduced rejection rates for both organs compared to single transplants. Short-term survival is acceptable, but long-term outcomes require further investigation.
Area of Science:
- Transplantation immunology
- Cardiovascular surgery
- Nephrology
Background:
- Combined heart-kidney transplantation (HNTx) is a rare procedure compared to single-organ or other combined transplants.
- Patients with end-stage heart and kidney disease are primary candidates for HNTx.
- HNTx is considered when significant disease is confined to the heart and kidneys.
Purpose of the Study:
- To review current experiences and outcomes of combined heart-kidney transplantation (HNTx).
- To assess rejection rates and survival in HNTx patients.
- To identify patient groups suitable for HNTx.
Main Methods:
- Literature review of existing reports on combined heart-kidney transplants.
- Analysis of patient selection criteria for HNTx.
- Evaluation of reported cardiac and renal rejection rates.
- Assessment of short-term patient survival data.
Main Results:
- HNTx patients demonstrate reduced cardiac rejection compared to heart-only transplants.
- Renal rejection rates in HNTx appear significantly lower than in kidney-only transplants.
- Simultaneous rejection of both transplanted organs is infrequent.
- Short-term patient survival in HNTx is reported as acceptable.
Conclusions:
- Combined heart-kidney transplantation may offer benefits in reducing organ rejection.
- Close surveillance of both heart and kidney is essential post-transplant.
- Long-term patient and graft survival data for HNTx are currently limited.
- Further multi-center studies are needed to establish long-term efficacy.
Abstract:
This review describes to date the experience with combined heart-kidney transplant (HNTx) from a single donor. HNTxs are very uncommon relative to single-organ transplants of the heart and kidney, as well as combined kidney-pancreas and combined kidney-liver transplants. Two groups of patients seem to be candidates for HNTx: 1) those with end-stage heart disease and fixed (nonreversible) renal disease, and 2) those with end-stage renal disease and severe cardiac disease unamenable to other treatment. In both groups, significant disease should be limited to the heart and kidney. Reports to date generally suggest decreased cardiac rejection in HNTx relative to heart-only transplants. Renal rejection in HNTx seems markedly reduced relative to kidney-only transplants. Simultaneous rejection of both organs is very uncommon, and, therefore, surveillance of both organs is necessary. Short-term patient survival seems to be acceptable in HNTx. Long-term patient and graft survival remains unknown, and further multi-center reports are needed.